Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.
QMRO Home
Barts Cancer Institute
Centre for Haemato-Oncology
Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.
QMRO Home
Barts Cancer Institute
Centre for Haemato-Oncology
Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors
Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.
Pagination
102089
DOI
10.1016/j.isci.2021.102089
Journal
iScience
ISSN
2589-0042
Metadata
Show full item record
Authors
Edelmann, J; Dokal, AD; Vilventhraraja, E; Holzmann, K; Britton, D; Klymenko, T; Döhner, H; Cragg, M; Braun, A; Cutillas, P
URI
https://qmro.qmul.ac.uk/xmlui/handle/123456789/70899
Collections
Centre for Haemato-Oncology
[217]